Diagnostic and predictive utility of serum homocysteine in diabetic nephropathy among type 2 diabetics

Vineet Kumar; Yuvraj Gulati; Richa Giri; Verma Rajendra Kumar Babulal

doi:10.18203/2349-3933.ijam20243815

Authors

Vineet Kumar Department of Medicine, GSVMMC, Kanpur, Uttar Pradesh, India
Yuvraj Gulati Department of Nephrology, GSVMMC, Kanpur, Uttar Pradesh, India
Richa Giri Department of Nephrology, GSVMMC, Kanpur, Uttar Pradesh, India
Verma Rajendra Kumar Babulal Department of Nephrology, GSVMMC, Kanpur, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20243815

Keywords:

Serum homocysteine, DN, Type 2 diabetes, Biomarkers, Renal impairment

Abstract

Background: Diabetic nephropathy (DN) is a leading cause of end-stage renal disease (ESRD) in patients with type 2 diabetes mellitus (T2DM). Early detection of DN is crucial for effective intervention, yet current biomarkers have limited sensitivity and specificity. Serum homocysteine, has been associated with vascular complications in diabetes and is hypothesized to be linked with DN. This study investigates the potential of elevated serum homocysteine levels as a marker for DN in T2DM patients.

Methods: A cross-sectional study was conducted involving 156 T2DM patients recruited from G. S. V. M. medical college, Kanpur. The inclusion criteria focused on adult patients with a confirmed diagnosis of T2DM. Exclusion criteria included conditions that could independently affect homocysteine levels or renal function. Statistical analyses were employed to assess the relationship between homocysteine levels and DN.

Results: The study found significantly higher homocysteine levels in patients with DN compared to those without DN. A positive correlation was observed between serum homocysteine levels and the severity of renal impairment, as indicated by a decline in glomerular filtration rate (GFR) and increased albuminuria. Logistic regression analysis confirmed that elevated serum homocysteine levels were an independent predictor of DN.

Conclusions: Elevated serum homocysteine levels are significantly associated with DN in T2DM patients and may serve as a useful biomarker for early detection and management of this complication. Given the limitations of current biomarkers, incorporating homocysteine measurements could improve the clinical management of patients at risk for DN.

Metrics

Metrics Loading ...

References

Varghese RT, Jialal I. Diabetic Nephropathy. In: StatPearls. StatPearls Publishing; 2024.

Yuan CM, Nee R, Ceckowski KA, Knight KR, Abbott KC. Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center. Clin Kidney J. 2016;10(2):257.

Pushpakumar S, Kundu S, Sen U. Endothelial Dysfunction: The Link Between Homocysteine and Hydrogen Sulfide. Curr Med Chem. 2014;21(32):3662.

Homocysteine-an overview. ScienceDirect Topics. Available at: https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/homocysteine. Accessed on 23 October 2024.

Diabetes Diagnosis amd Tests | ADA. Available at: https://diabetes.org/about-diabetes/diagnosis. Accessed on 23 October 2024.

What is High-Performance Liquid Chromatography (HPLC)? | Agilent. Available at: https://www.agilent.com/en/product/liquid-chromatography/hplc-fundamentals. Accessed on 24 October 2024.

eGFR Calculator. National Kidney Foundation. Available at: https://www.kidney.org/professionals/gfr_calculator. Accessed on 23 October 2024.

Downloading IBM SPSS Statistics 25. Available at: https://www.ibm.com/support/pages/downloading-ibm-spss-statistics-25. Accessed on 24 October 2024.

Ozmen B, Ozmen D, Turgan N, Habif S, Mutaf I, Bayindir O. Association between homocysteinemia and renal function in patients with type 2 diabetes mellitus. Ann Clin Lab Sci. 2002;32(3):279-86.

Looker HC, Fagot-Campagna A, Gunter EW, Pfeiffer CM, Venkat Narayan KM, et al. Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes. Diabetologia. 2003;46(6):766-72.

Ma L, Liu Q, Jiang Y, Hailing Z, Tingting Z, Yongtong C, t al. Genetically elevated circulating homocysteine concentrations increase the risk of diabetic kidney disease in Chinese diabetic patients. J Cell Mol Med. 2019;23(4):2794-800.

Xu W, Tang S, Xiang M, Peng J. Serum Homocysteine, cystatin C as Biomarkers for Progression of Diabetic Nephropathy. Pteridines. 2019;30(1):183-8.

Association between homocysteine status and the risk of nephropathy in type 2 diabetes mellitus | Request PDF. Available at: https://www.researchgate.net/publication/260241253_Association_between_homocysteine_status_and_the_risk_of_nephropathy_in_type_2_diabetes_mellitus. Accessed on 5 December 2024.

Zheng X, Liu Q, Liu Z. Serum homocysteine concentration as a marker for advanced diabetic nephropathy in a cohort of elderly patients. BMC Endocr Disord. 2023;23(1):114.

Francis ME, Eggers PW, Hostetter TH, Briggs JP. Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney Int. 2004;66(1):303-12.

House AA, Eliasziw M, Cattran DC. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA. 2010;303(16):1603-9.